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Medications are used for a wide variety of indications during space flight. For 
example, astronauts have taken drugs in flight to ameliorate or prevent symptoms of 
space motion sickness, headache, sleeplessness, backache, nasal congestion, and 
constipation. Russian cosmonauts reportedly take medications to prevent metabolic 
disturbances of the myocardium and intestinal flora, and to optimize their work capacity. 
Although the discomfort associated with some acute responses to microgravity (e.g., 
space motion sickness) is expected to diminish with length of time in flight, other 
responses that have delayed onset (e.g., maintaining nutritional status, bone and muscle 
strength, and perhaps immune response) may affect health and quality of life during 
longer missions. Therefore, as the duration of space flights increases, the need for 
treatment with medications is expected to increase accordingly. 
Medications carried on Space Shuttle missions have varied somewhat from flight 
to flight, depending on the individual needs of the crewmembers. Medications use during 
Shuttle flights seems to be more prevalent than during earlier programs, perhaps because 
drugs are provided in easy-to-use forms. In fact, nearly all medications taken to date 
have been ingested orally in tablet form. However, given that the oral route may not be 
ideal for those suffering motion-sickness symptoms, intramuscular and intranasal 
preparations are being tested. For example, intramuscular administration of 
promethazine hydrochloride (Phenergan@) has been reported to be more effective in 
alleviating motion-sickness symptoms. The difficulties involved in conducting definitive 
studies of drug efficacy during U.S. space flights have been compounded by the absence 
of a systematic approach to determining which drugs were taken by whom and under 
what circumstances. 
The use of some drugs in space has been less efficacious than expected. The 
onset, intensity, and duration of the response produced by any drug depend upon rates of 
absorption, distribution, metabolism, and elimination of the drug; space flight-induced 
changes in blood flow and the fbnction of the gastrointestinal (GI) tract, liver, or kidneys 
may alter these processes. Another important aspect of clinical efficacy of medications in 
space is the stability of pharmaceuticals. As the U.S. space program is moving toward 
extended Space Shuttle flights and beyond, to space station missions and planetary 
explorations, understanding how space flight affects organ systems and clinical 
pharmacology is necessary to optimize pharmacotherapeutics in space and ensure 
adequate safety and health of crewmembers. 
provide safe and effective diagnostic and pharmacological intervention products, 
procedures and strategies in support of successfbl space medical operations. To achieve 
this overall goal, research objectives conceived are to: 1) Identify physiologic, 
pharmacokinetic and pharmacodynamic changes in space; 2) Develop safe and effective 
non-invasive sustained-release dosage forms and regimens for pharmacological 
interventions in space, and; 3) Create and maintain a comprehensive space 
pharmacokinetic, pharmacodynamic and therapeutic database. 
The goal of pharmacotherapeutics research at the Johnson Space Center is to 
https://ntrs.nasa.gov/search.jsp?R=20050220667 2019-08-29T20:56:04+00:00Z
e 
Because the physiologic effects of microgravity develop over hours, days, or 
weeks, it is to be expected that the effects of some medications will change with 
increasing time spent in space. It should be possible, at least in principle, to assess some 
of these changes under experimental conditions on Earth. To be significant for space 
medicine, however, in-flight trials must take place, with replications before and after 
flight on Earth, in order to assess variations within and between individuals. In view of 
the heavy workload of flight crews and the present dificulties of performing meaningful 
pharmacokinetic-pharmacodynamic assessments with humans in space, serious thought 
should be given to in-flight animal experiments, with concurrent Earth-based controls. 
Another important aspect of pharmacotherapeutics research should concentrate on the 
development of therapeutic drug monitoring and chronic drug delivery technologies that 
can meet the challenges of remote treatment needs for the Space Station and exploration- 
class missions, e.g., to the moon and Mars. 
In classic ground-based pharmacokinetic studies, estimates of the rates of 
absorption, distribution, metabolism, and excretion of compounds are calculated from 
measuring the amount of the drug and its metabolites in plasma as a hnction of time. 
Logistical problems (e.g., lack of refrigerated storage, difficulty drawing blood in 
microgravity), as well as the desire to minimize the number of invasive procedures that 
the astronauts must undergo, have led tc  efforts to develop less invasive means s ~ c h  as
salivary drug monitoring to examine the fate of drugs in the body. 
characteristics of drugs on Earth, including the molecular basis of xenobiotic transport 
and biotransformation, much less is known about the mechanisms by which drugs elicit 
their effects, whether desired or adverse. This lack of knowledge severely limits the 
ability to predict the pharmacodynamic changes that may occur during space flight. 
Because changes in the dose-response relationship can be caused by changes in 
pharmacokinetics, pharmacodynamics, or both, data must be obtained to delineate the 
dose-concentration from the concentration-effect components. Other potential sources of 
response-variation include stress, lack of sleep, and changes in chronophysiologic status 
This implies the need for in-flight assessment of therapeutic response and optimization of 
dosage regimens based on that response. 
Concurrent with noninvasive pharmacokinetic/p harmacodynamic methods 
development and assessment, design and development of alternatives to enteral dosage 
forms are also pursued. Data currently available suggest that space flight affects 
absorption of orally administered medications and stability of drug formulations. These 
findings support the need for the development of novel drug delivery systems for acute 
and chronic treatment in space. 
In conclusion, optimization of therapeutics for space exploration requires research 
and development of enabling technologies and methods for the diagnosis and treatment of 
acute and chronic ailments encountered by astronauts while in space and upon return to 
Earth. 
Although much is known about the processes that constitute the pharmacokinetic 
